HIV seroconversions and genotypic viral resistance profiles in the PrEP impact trial.

Abstract

Objectives: Here we describe HIV seroconversion events in participants of thePrEP Impact trial.Methods: Of 24 268 participants, we reviewed data for the 54 who were diagnosed with HIV during the trial; 11 at baseline.Results: Incidence was low for those diagnosed pre-pandemic at 0.13 per 100person-years, and mainly linked to low self-reported adherence. The emer-gence of drug resistance in participants reporting recent oral PrEP (tenofovirdisoproxil maleate with emtricitabine (TDF/FTC)) exposure was low (whereanalysis results are available, 21% of participants who seroconverted duringtrial participation showed drug resistance).Conclusions: Oral PrEP TDF/FTC is an effective HIV prevention interven-tion. Further data are needed to assess the prevalence and impact of increasingoral PrEP TDF/FTC use on HIV resistance.